Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.

ABSTRACT: Technologies required to generate induced pluripotent stem cells (iPSC) were first described 15 years ago, providing a strong impetus to the field of regenerative medicine. In parallel, immunotherapy has finally emerged as a clinically meaningful modality of cancer therapy. In particular, impressive efficacy has been achieved in patients with selected haematological malignancies using ex vivo expanded autologous T cells engineered to express chimeric antigen receptors (CARs). While solid tumours account for over 90% of human cancer, they currently are largely refractory to this therapeutic approach. Nonetheless, given the considerable innovation taking place worldwide in the CAR field, it is likely that effective solutions for common solid tumours will emerge in the near future. Such a dev

SUBMITTER: Mazza R 

PROVIDER: S-EPMC8666432 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature